All posts by PIER MARIA FORNASARI

PIER MARIA FORNASARI
2020-01-29

New gene correction therapy for Duchenne muscular dystrophy. Gene scissors against incurable muscular disease

Duchenne type muscular dystrophy (DMD) is the most common hereditary muscular disease among children, leaving them wheelchair-bound before the age of twelve and reducing life expectancy. Researchers at Technical University of Munich (TUM), Ludwig Maximilian University of Munich (LMU) and the German Research Center for Environmental Health (Helmholtz Zentrum München) have developed a gene therapy

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2020-01-29

European Medicines Agency Validates Kite’s Marketing Application for Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma

Investigational KTE-X19 To Be First Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma in Europe if Approved Kite, a Gilead Company, today announced that the company’s Marketing Authorization Application (MAA) for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL),

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2020-01-29

EC approves Siponimod for secondary progressive multiple sclerosis

Mayzent (siponimod) has been approved by the European Commission (EC) for adults with secondary progressive multiple sclerosis (SPMS) based on the results of the EXPAND trial. The European Commission (EC) has approved Mayzent (siponimod) for the treatment of adults with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. Approximately 80

Read More

No Comments InEMA
PIER MARIA FORNASARI
2020-01-28

R&D plans are the stars in new EU industrial strategy and “Wholly Inclusive” European Research Area

A draft plan, for adoption in Brussels on 4 March, highlights the importance of research and innovation in making EU industry more competitive Source Science Business The new European Commission is putting research and innovation at the heart of its ambitious new industrial strategy. A draft memo on the strategy, dated 14 January, for a

Read More

No Comments InRESEARCH
PIER MARIA FORNASARI
2020-01-28

Mapping the Wuhan Coronavirus (2019-nCoV) Johns Hopkins CSSE Online Dashboard

Source CSSE Online Dashboard Background On December 31, 2019, the World Health Organization (WHO) was informed of an outbreak of “pneumonia of unknown cause” detected in Wuhan City, Hubei Province, China – the seventh-largest city in China with 11 million residents. As of January 23, there are over 800 cases of 2019-nCoV confirmed globally, including cases in

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2020-01-28

Patient in Osaka University 1st to have iPS cell heart muscle transplant

A patient who received the world’s first transplant of cardiac muscle cells using artificially derived stem cells known as iPS cells this month is in stable condition, an Osaka University team said Jan. 27. After surgery, doctors closely monitored the patient, who had ischemic cardiomyopathy, a condition in which clotted arteries cause heart muscles to

Read More

No Comments InTISSUE ENGINEERING
PIER MARIA FORNASARI
2020-01-28

FDA Announces Key Actions to Advance Development of Novel Coronavirus Medical Countermeasures

Today, the U.S. Food and Drug Administration (FDA) announced critical actions to advance development of novel coronavirus medical countermeasures. As with any emerging public health threat, the FDA will collaborate with interagency partners, product developers, international partners and global regulators to expedite the development and availability of medical products needed to diagnose, treat, mitigate and

Read More

No Comments InWELLNESS